ABSTRACT
Nomegestrol acetate (NOMAC) combined with E2 (Zoely) is a monophasic oral contraceptive (OC) which safety and efficacy was confirmed in a number of level I evidence clinical trials. Zoely is highly effective OC, especially in overweight and obese patients, with good cycle control, safe and well tolerated. NOMAC/E2 combination causes no or minimal weight gain and is characterized by minimal influence on bone mineral density or blood pressure and presence of acne. Moreover lipids profile, carbohydrates metabolism, haemostasis and endocrine glands functioning were not affected. High tolerance and acceptance of NOMAC/E2 combination by women, low adverse event profile, fast recovery of ovarian activity and ovulation is a reasonable treatment tool in everyday practice.
Subject(s)
Contraceptives, Oral, Combined/administration & dosage , Contraceptives, Oral, Synthetic/administration & dosage , Estradiol/administration & dosage , Megestrol/administration & dosage , Norpregnadienes/administration & dosage , Practice Guidelines as Topic , Adult , Female , Gynecology/standards , Humans , Inservice Training/standards , National Health Programs/standards , Obstetrics/standards , Ovulation/drug effects , Poland , Young AdultABSTRACT
Recent epidemiologic studies indicate that use of combined oral contraception is associated with a increase in the incidence of cardiovascular disease (venous thromboembolism, pulmonary embolism, myocardial infarction and stroke). The risk of cardiovascular disease is strongly related to estrogen dose, progestogen type and other factors for example thrombogenic mutations and cigarette smoking among female over age 35. The progestogen only contraception is safe alternative to combined hormonal contraception. Progestogen only pill (POP) has different levels of action (local and/or central) which may vary from one drug to another. As for the cardiovascular disease risk, progestogens are not considered to be risk factors. Desogestrel containing POP is advised in the following cases: bad tolerance of exogenous oestrogens; in order to counteract an endogenous hyperoestrogenosis; medical, metabolic or cardiovascular contraindications to estroprogestogen contraception. Lastly, POP should be used as a prime contraception in some particular situations (breast feeding, endometriosis, adenomyosis, cigarette smoking, contraception for older women). These recommendations present the actual system of care in that population of women in Poland.
Subject(s)
Cardiovascular Diseases/prevention & control , Contraceptives, Oral, Synthetic/administration & dosage , Desogestrel/administration & dosage , Progestins/administration & dosage , Women's Health , Age Factors , Contraceptives, Oral/standards , Contraceptives, Oral, Synthetic/standards , Desogestrel/standards , Female , Humans , Inservice Training/standards , National Health Programs/standards , Poland , Progestins/standards , Quality Assurance, Health Care/standards , Risk Factors , Societies, Medical/standards , Women's Health Services/organization & administrationABSTRACT
Vulvovaginal infection is the most common cause of gynecological problems in sexually active women. Few years ago it was not considered as serious disease which may cause major health implications. Currently we are aware that it implies life worsening, temporal indisposition, postoperative complications and even life threatening sepsis in patients hospitalized in Intensive Care Units. Knowledge about pharmacological properties of drugs used in treatment vulvovaginal candidiasis allows for tailoring therapy to each patient. Fluconazole is modern and up to date option for treatment of VVC/rVVC. Short- and long-term therapeutic efficacy of fluconazole was confirmed in numerous high reliability clinical trials. Good tolerance, wide range of single therapeutic dose and high level of patient's acceptance gives the specialist powerful and efficient tool for management of VVC/rVVC.